Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.62 Insider Own0.01% Shs Outstand84.49M Perf Week-1.54%
Market Cap13.52M Forward P/E- EPS next Y-1.21 Insider Trans0.00% Shs Float84.49M Perf Month-55.32%
Income-116.66M PEG- EPS next Q-0.24 Inst Own19.88% Short Float1.48% Perf Quarter-43.50%
Sales7.77M P/S1.74 EPS this Y-102.91% Inst Trans16.46% Short Ratio0.57 Perf Half Y-71.43%
Book/sh1.80 P/B0.09 EPS next Y30.95% ROA-61.38% Short Interest1.25M Perf Year-95.01%
Cash/sh0.30 P/C0.54 EPS next 5Y- ROE-74.61% 52W Range0.12 - 3.31 Perf YTD-60.30%
Dividend Est.- P/FCF- EPS past 5Y79.31% ROI-103.50% 52W High-95.17% Beta2.21
Dividend TTM- Quick Ratio1.78 Sales past 5Y0.00% Gross Margin-15.90% 52W Low33.11% ATR (14)0.03
Dividend Ex-Date- Current Ratio2.53 EPS Y/Y TTM66.26% Oper. Margin-1523.94% RSI (14)28.92 Volatility14.53% 15.29%
Employees103 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin-1501.78% Recom1.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q75.21% Payout- Rel Volume0.49 Prev Close0.16
Sales Surprise50.35% EPS Surprise-368.12% Sales Q/Q- EarningsApr 01 AMC Avg Volume2.19M Price0.16
SMA20-25.52% SMA50-46.43% SMA200-74.40% Trades Volume1,082,176 Change1.91%
Date Action Analyst Rating Change Price Target Change
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Apr-09-24 06:31AM
Apr-01-24 04:15PM
Mar-28-24 09:32AM
Mar-25-24 08:00AM
Mar-24-24 04:05PM
08:00AM Loading…
Mar-21-24 08:00AM
Mar-20-24 08:00AM
Mar-19-24 08:00AM
Mar-12-24 08:00AM
Mar-11-24 08:00AM
Mar-07-24 09:37AM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Feb-29-24 08:00AM
08:00AM Loading…
Feb-28-24 08:00AM
Feb-27-24 08:00AM
Feb-26-24 08:00AM
Feb-25-24 02:12PM
Feb-23-24 09:30AM
Feb-20-24 08:00AM
Feb-16-24 09:30AM
Feb-15-24 08:45AM
Feb-14-24 08:00AM
Feb-13-24 08:00AM
Feb-12-24 08:00AM
Feb-01-24 08:00AM
07:00AM Loading…
Jan-31-24 07:00AM
Jan-30-24 05:00PM
Jan-29-24 07:00AM
Jan-26-24 05:31PM
Jan-25-24 07:00AM
Jan-24-24 03:28PM
Jan-09-24 07:00AM
Jan-03-24 07:00AM
Jan-02-24 06:08AM
Dec-20-23 10:35AM
Dec-14-23 09:15AM
Dec-12-23 01:40PM
Dec-11-23 07:00AM
Dec-04-23 07:00AM
Nov-28-23 07:00AM
Nov-20-23 01:57PM
Nov-15-23 07:00AM
Nov-13-23 07:00AM
Nov-09-23 04:15PM
Nov-02-23 08:00AM
Oct-31-23 05:00PM
Oct-30-23 07:00AM
Oct-26-23 07:00AM
Oct-25-23 08:45AM
Oct-19-23 07:00AM
Oct-18-23 07:00AM
Oct-16-23 07:00AM
Oct-12-23 07:00AM
Oct-11-23 07:00AM
Oct-09-23 07:00AM
Oct-04-23 07:00AM
Sep-28-23 09:00PM
Sep-27-23 08:30AM
Sep-26-23 10:18AM
Sep-21-23 07:00AM
Sep-19-23 01:54PM
Sep-18-23 07:00AM
Sep-15-23 09:30AM
Sep-14-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:32AM
Aug-28-23 01:13PM
Aug-21-23 01:18PM
Aug-17-23 07:00AM
Aug-16-23 07:00AM
Aug-10-23 04:30PM
Aug-07-23 07:00AM
Aug-01-23 04:01PM
Jul-31-23 07:00AM
Jul-27-23 09:31PM
Jul-26-23 04:05PM
Jul-24-23 07:00AM
Jul-17-23 07:00AM
Jul-10-23 07:00AM
Jul-06-23 08:09AM
Jul-03-23 07:00AM
Jun-28-23 03:21PM
Jun-26-23 07:00AM
Jun-21-23 08:25AM
Jun-15-23 07:00AM
Jun-07-23 07:00AM
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.